FDA Approves Niktimvo for Treatment of Chronic Graft-Versus-Host Disease’
WILMINGTON, Del. and WALTHAM, Mass. Incyte (Nasdaq: INCY) and Syndax Pharmaceuticals (Nasdaq: SNDX) announced today that the U.S. Food and Drug Administration (FDA) has approved Niktimvo (axatilimab-csfr) for the treatment of chronic graft-versus-host disease (GVHD). This significant development comes after patients have failed to respond to at least two prior systemic therapies.
Niktimvo is a monoclonal antibody targeting CSF-1R, a cell surface protein involved in the regulation of immune responses. The approval from the FDA allows its use in both adult and pediatric patients weighing at least 40 kilograms (approximately 88.2 pounds) who have not responded adequately to other treatments.
Chronic graft-versus-host disease is a condition that can occur in patients who have undergone stem cell or bone marrow transplants. It arises when donor immune cells attack the patient’s body, leading to a range of complications that can seriously affect quality of life and may even be life-threatening.
The approval of Niktimvo marks a noteworthy advancement in the treatment options available for GVHD, a condition with limited therapeutic alternatives. Both Incyte and Syndax are optimistic that this new therapy can provide meaningful relief for affected patients and improve their overall outcomes.
As the medical community anticipates the distribution of Niktimvo following its approval, both companies are prepared to initiate programs aimed at ensuring healthcare providers and patients have access to this potentially life-changing treatment.
The approval highlights a growing focus on innovative therapies that harness specific immunological pathways, addressing the unmet needs in complex immunological conditions such as GVHD.
Comments